Glenmark’s consolidated revenue increases by 10.62 per cent to Rs 66447.68 million in FY 14-15

Consolidated revenue in Q4 FY14-15 was Rs 17758.13 million an increase of 4.24 per cent

Glenmark Pharmaceuticals announced its results for the fourth quarter and year ended March, 31, 2015. For the fourth quarter ended March 31, 2015, Glenmark’s consolidated revenue was at Rs 17,758.13 million ($ 285.38 million) as against Rs 17035.60 million ($ 276.86 million). For the year ended March 31, 2015, Glenmark’s consolidated revenue was at Rs 66,447.68 ($ 1086.19 million) as against Rs 60,069.35 ($ 994.09 million) recording an increase of 10.62 per cent. Consolidated net profit was at Rs 106.13 million for the quarter and Rs 4753.10 million for the year ended March, 31, 2015.

“We continue to record good growth in our India, LatAm and Europe businesses. Currency devaluation and subdued business environment persisted to impact our Rest of the World, especially Russian operations. We have been also making steady progress in our innovation pipeline with our three NCE and four NBE molecules in development,” said Glenn Saldanha, Chairman and Managing Director, Glenmark Pharmaceuticals.